Market Place
Sourcing Support
Equillium to Present at the Stifel Healthcare Conference
13 Nov 2024 //
BUSINESSWIRE
Equillium Reports Q3 2024 Financial Results & Corporate Updates
13 Nov 2024 //
BUSINESSWIRE
Equillium Announces Poster Presentation at SITC Conference
12 Nov 2024 //
BUSINESSWIRE
Equillium Maintains Itolizumab Rights After Ono Partnership
31 Oct 2024 //
BUSINESSWIRE
Vivtex And Equillium Partner On GI-Targeted Formulations
16 Sep 2024 //
GLOBENEWSWIRE
Equillium To Present At Stifel Virtual Inflammation Summit
10 Sep 2024 //
BUSINESSWIRE
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04 Sep 2024 //
BUSINESSWIRE
Equillium To Present At Two Upcoming Investor Conferences
28 Aug 2024 //
BUSINESSWIRE
Equillium Reports Q2 2024 Results And Corporate Highlights
08 Aug 2024 //
BUSINESSWIRE
Equillium Announces Positive Analysis from Phase 3 EQUATOR Study of Itolizumab
06 Aug 2024 //
BUSINESSWIRE
Equillium Announces Second Quarter 2024 Estimated Cash and Investments Balance
18 Jul 2024 //
BUSINESSWIRE
Equillium to be included in the Russell Microcap® Index
12 Jun 2024 //
BUSINESSWIRE
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05 Jun 2024 //
BUSINESSWIRE
Equillium: Positive Phase 2 EQ101 Data In Alopecia Areata
04 Jun 2024 //
BUSINESSWIRE
Equillium to Present at the Jefferies Global Healthcare Conference
29 May 2024 //
BUSINESSWIRE
Equillium Announces Interim EQUATOR GVHD Enrollment Achieved
14 May 2024 //
BUSINESSWIRE
Equillium Q1 2024 Financials, Clinical Highlights
09 May 2024 //
BUSINESSWIRE
Equillium Presenting At American Association of Immunologists Meeting
07 May 2024 //
BUSINESSWIRE
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03 Apr 2024 //
BUSINESSWIRE
Equillium Announces Positive Data from the Ph 1b EQUALISE study
01 Apr 2024 //
BUSINESSWIRE
Equillium delivers new lupus data to Ono`s doorstep
01 Apr 2024 //
FIERCE BIOTECH
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results
25 Mar 2024 //
BUSINESSWIRE
Equillium to Present at the H.C. Autoimmune & Inflammatory Disease Conference
22 Mar 2024 //
BUSINESSWIRE
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102
21 Dec 2023 //
BUSINESSWIRE
Equillium swaps subcutaneous cytokine inhibitor for oral option
21 Dec 2023 //
FIERCE BIOTECH
Equillium Presents Positive Data from Phase 1b EQUALISE Study
13 Nov 2023 //
BUSINESSWIRE
Equillium Reports Third Quarter 2023 Financial Results
08 Nov 2023 //
BUSINESSWIRE
Equillium Announces Data from Phase 1b EQUALISE Study Presented
06 Nov 2023 //
BUSINESSWIRE
Equillium Announces Abstracts Accepted for Presentation at 2023 Annual Meetings
19 Oct 2023 //
BUSINESSWIRE
Equillium Announces Data from Deliverable Multi-Cytokine Inhibitor
16 Oct 2023 //
BUSINESSWIRE
Equillium to Host Analyst & Investor Day
03 Oct 2023 //
BUSINESSWIRE
Equillium to Present at the JonesTrading 2023 Healthcare Summit
02 Oct 2023 //
BUSINESSWIRE
Equillium to Present at the Cantor Fitzgerald Global Healthcare
20 Sep 2023 //
BUSINESSWIRE
Equillium to Attend Wells Fargo Healthcare Conference 25th Annual Conference
30 Aug 2023 //
BUSINESSWIRE
Equillium Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
BUSINESSWIRE
Equillium Announces $7.5 Million Share Repurchase Program
02 Aug 2023 //
BUSINESSWIRE
Equillium to Present at the Jefferies Global Healthcare Conferences
01 Jun 2023 //
BUSINESSWIRE
Equillium Announces Poster Presentation at the Annual Meeting
15 May 2023 //
BUSINESSWIRE
Equillium Reports First Quarter 2023 Financial Results
11 May 2023 //
BUSINESSWIRE
Equillium Announces Poster Presentation at the Annual Meeting European Society
24 Apr 2023 //
BUSINESSWIRE
Equillium Reports Fourth Quarter and Full Year 2022 Financial Results
23 Mar 2023 //
BUSINESSWIRE
Equillium to Present at the H.C. Wainwright Autoimmune Conference
22 Mar 2023 //
BUSINESSWIRE
Equillium Announces Oral Presentation at the Tandem Meetings of ASTCT and CIBMTR
17 Feb 2023 //
BUSINESSWIRE
Equillium to Present at the SVB Securities Annual Global Healthcare Conference
07 Feb 2023 //
BUSINESSWIRE
Equillium Announces Abstract Accepted for Oral Presentation at ASTCT & CIBMTR
13 Jan 2023 //
BUSINESSWIRE
Equillium is no longer buying Metacrine, citing new cash
27 Dec 2022 //
FIERCEBIOTECH
Equillium and Metacrine Mutually Agree to Terminate Definitive Merger Agreement
23 Dec 2022 //
BUSINESSWIRE
Biocon starts clinical study to evaluate efficacy of Itolizumab
15 Dec 2022 //
ECONOMIC TIMES
Equillium and Ono Pharmaceutical Announce Agreement for Itolizumab
06 Dec 2022 //
BUSINESSWIRE
Equillium Announces Data Suggesting Soluble ALCAM as a Potential Biomarker
14 Nov 2022 //
BUSINESSWIRE
Equillium Reports Third Quarter 2022 Financial Results
14 Nov 2022 //
BUSINESSWIRE
Equillium Announces Initiation of Ph2 study of EQ101
10 Nov 2022 //
BUSINESSWIRE
Equillium begins Phase I trial of coeliac disease therapy
03 Nov 2022 //
CLINICALTRIALSARENA
Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class
02 Nov 2022 //
BUSINESSWIRE
Equillium to present of Data Demonstrating Importance of EQ101 & EQ102
26 Oct 2022 //
BUSINESSWIRE
Equillium Announces Positive Interim Results from the EQUALISE Study
27 Sep 2022 //
BUSINESSWIRE
Equillium Announces Abstract Accepted for Presentation at ACR Convergence 2022
15 Sep 2022 //
BUSINESSWIRE
Equillium to Acquire Metacrine in All-Stock Transaction
06 Sep 2022 //
BUSINESSWIRE
Equillium to Present at Two Upcoming Investor Conferences
31 Aug 2022 //
BUSINESSWIRE
Equillium Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
BUSINESSWIRE
